MEREO BIOPHARMA GROUP PLC Cash And Cash Equivalents
MEREO BIOPHARMA GROUP PLC (MREO) had Cash And Cash Equivalents of GBP 42.11 million as of 2023-06-30, per its 6-K filed 2023-09-07.
Discontinued › Balance Sheet › Assets › Cash and Cash Equivalent
ifrs-full:CashAndCashEquivalents · last filed 2023-09-07
- 2023-06-30: Cash And Cash Equivalents 42.11M GBP.
- 2022-12-31: Cash And Cash Equivalents 56.33M GBP.
- 2022-06-30: Cash And Cash Equivalents 76.42M GBP.
- 2021-12-31: Cash And Cash Equivalents 94.30M GBP.
| Period end | Cash And Cash Equivalents | Cash And Cash Equivalents as first filed |
|---|---|---|
| 2023-06-30 | 42.11M GBP 6-K · filed 2023-09-07 | |
| 2022-12-31 | 56.33M GBP 6-K · filed 2023-09-07 | |
| 2022-06-30 | 76.42M GBP 6-K · filed 2023-09-07 | |
| 2021-12-31 | 94.30M GBP 6-K · filed 2023-09-07 | |
| 2021-06-30 | 110.09M GBP 6-K · filed 2022-11-02 | |
| 2020-12-31 | 23.47M GBP 20-F · filed 2023-03-28 | |
| 2020-06-30 | 56.82M GBP 6-K · filed 2021-11-02 | |
| 2019-12-31 | 16.35M GBP 20-F · filed 2023-03-28 | |
| 2019-06-30 | 28.29M GBP 6-K · filed 2020-09-29 | |
| 2018-12-31 | 25.04M GBP 20-F · filed 2022-03-31 | 25.04M GBP 20-F/A · filed 2019-05-29 |
| 2017-12-31 | 50.05M GBP 20-F · filed 2021-03-31 | 50.04M GBP 20-F/A · filed 2019-05-29 |
| 2016-12-31 | 53.58M GBP 20-F · filed 2020-06-15 | 53.58M GBP 20-F/A · filed 2019-05-29 |
| 2015-12-31 | 12.25M GBP 20-F/A · filed 2019-05-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |